• RxStrategies Clinical Insights – April 2015 Issue 1

    Welcome to the April edition of RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place.   New Drug Approvals Corlanor® (ivabradine) April 15, 2015 – The U.S. Food and Drug Administration approved Corlanor® (ivabradine) to reduce hospitalization from worsening heart failure. Corlanor® is approved for use… Read more »

  • RxStrategies Clinical Insights – March Issue 2

    Welcome to the March second edition of RxStrategies Clinical Insights, a concise communication to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place.   New Drug Approvals Anthrasil™ (Anthrax Immune Globulin Intravenous – Human) – New Drug Approval March 25, 2015 – The U.S. Food and Drug Administration approved… Read more »

  • RxStrategies Clinical Insights – February/March 2015, Issue 1

    Welcome to the February/March edition of RxStrategies Clinical Insights, a concise communication to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place. New Drug Approvals Avycaz™ (ceftazidime-avibactam) February 25, 2015 — The U.S. Food and Drug Administration approved Avycaz (ceftazidime-avibactam), a new antibacterial drug product, to treat adults with… Read more »

  • RxStrategies Clinical Insights – January 2015, Issue 1

    Welcome to the January edition of RxStrategies Clinical Insights, a concise communication to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place.   New Drug Approvals Savaysa™ (edoxaban tablets) January 8, 2015 — The U.S. Food and Drug Administration approved the anti-clotting drug Savaysa™ (edoxaban tablets) to reduce the risk of… Read more »

  • RxStrategies Clinical Insights – December 2014, Issue 1

    Welcome to the December edition of RxStrategies Clinical Insights, a concise communication to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place.   New Drug Approval Blincyto™ (blinatumomab) December 3, 2014 – The U.S. Food and Drug Administration approved Blincyto™(blinatumomab) to treat patients with Philadelphia chromosome-negative precursor B-cell acute… Read more »

  • RxStrategies Clinical Insights – November 2014, Issue 2

    Welcome to the second November edition of RxStrategies Clinical Insights, a concise communication to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place.   New Drug Approvals Lemtrada™ (alemtuzumab) November 14, 2014—The U.S. Food and Drug Administration has approved Lemtrada™ (alemtuzumab) as a disease-modifying therapy for people with relapsing forms of Multiple… Read more »

  • RxStrategies Clinical Insights – October 2014, Issue 1

    New Drug Approvals Esbriet® (pirfenidone), Ofev® (nintedanib)– New Drug Approval (Orphan Drug) October 15, 2014 – The U.S. Food and Drug Administration announced the approval of Esbriet® (pirfenidone) and Ofev® (nintedanib) for the treatment of idiopathic pulmonary fibrosis (IPF). IPF is a condition in which the lungs become progressively scarred over time. As a result,… Read more »

  • RxStrategies Clinical Insights – September 2014, Issue 2

    Welcome to this month’s second edition of RxStrategies Clinical Insights, a concise communication to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place.    New Drug Approvals Trulicity™ (dulaglutide) – New Drug Approval September 18, 2014 – The U.S. Food and Drug Administration approved Trulicity™ (dulaglutide), a once-weekly subcutaneous injection to improve… Read more »

  • RxStrategies Clinical Insights – September 2014, Issue 1

    Welcome to this month’s RxStrategies Clinical Insights, a concise communication to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place.   New Drug Approvals Keytruda® (pembrolizumab) – New Orphan Drug Approval September 4, 2014 – The U.S. Food and Drug Administration approvedKeytruda® (pembrolizumab) for treatment of patients with advanced or unresectable… Read more »

  • RxStrategies Clinical Insights – August 2014

     Download print version. Welcome to this month’s RxStrategies Clinical Insights, a concise communication to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place. New Drug Approvals Cerdelga™ (eliglustat) – New Orphan Drug Approval August 19, 2014 – The U.S. Food and Drug Administration approved Cerdelga™ (eliglustat) for the long-term treatment of… Read more »